Macrophage inflammatory protein-3α is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 6979-6987

  Chang, Kai Ping ^a   Hao, Sheng Po ^a   Chang, Jui Hung ^a   Wu, Chih Ching ^a   Tsang, Ngan Ming ^a   Lee, Yun Shien ^a   Hsu, Chen Lung ^a   Ueng, Shir Hwa ^a   Liu, Shiau Chin ^a   Liu, Yu Lun ^a   Wei, Pei Cih ^a   Liang, Yin ^a   Chang, Yu Sun ^a   Yu, Jau Song ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN A; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; CAPSID PROTEIN; CCL20 PROTEIN, HUMAN; EPSTEIN BARR VIRAL CAPSID ANTIGEN; EPSTEIN-BARR VIRAL CAPSID ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CELL FUNCTION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DISEASE FREE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TREATMENT OUTCOME; VIRUS CAPSID; VIRUS LOAD; BLOOD; CELL MOTION; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; NASOPHARYNX TUMOR; PROGNOSIS;

ANTIGENS, VIRAL; CAPSID PROTEINS; CELL MOVEMENT; CHEMOKINE CCL20; DISEASE-FREE SURVIVAL; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149242892     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0090     Document Type: Article

References (38)

1. Cheng SH, Jian JJ, Tsai SY, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2000;48:1323-30.
2. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-7.
3. Chang KP, Hao SP, Lin SY, et al. The 30-bp deletion of Epstein-Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma. Laryngoscope 2006;116:541-6.
4. Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261-70.
5. Chang YS, Tyan YS, Liu ST, Tsai MS, Pao CC. Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. JClin Microbiol 1990;28:2398-402.
6. Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. Semin Cancer Biol 1992;3:297-307.
7. Wu TC, Mann RB, Epstein JI, et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol 1991;138:1461-9.
8. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976;17:1-7.
9. Ho HC, Ng MH, Kwan HC, Chau JC. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer 1976;34:655-60.
10. Fan H, Nicholls J, Chua D, et al. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 2004;112:1036-41.
11. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-70.
12. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
13. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002;13:143-54.
14. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004;14:181-5.
15. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-76.
16. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001;78:57-110.
17. Homey B, eu-Nosjean MC, Wiesenborn A, et al. Upregulation of macrophage inflammatory protein-3α/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000;164:6621-32.
18. Matsui T, Akahoshi T, Namai R, et al. Selective recruitment of CCR6-expressing cells by increased production of MIP-3α in rheumatoid arthritis. Clin Exp Immunol 2001;125:155-61.
19. Nakayama T, Fujisawa R, Yamada H, et al. Inducible expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3α/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int Immunol 2001;13:95-103.
20. Kleeff J, Kusama T, Rossi DL, et al. Detection and localization of Mip-3α/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer 1999;81:650-7.
21. Kimsey TF, Campbell AS, Albo D, Wilson M, Wang TN. Co-localization of macrophage inflammatory protein-3α (Mip-3α) and its receptor, CCR6, promotes pancreatic cancer cell invasion. Cancer J 2004;10:374-80.
22. O'Sullivan B, Shah J. New TNM staging criteria for head and neck tumors. Semin Surg Oncol 2003;21:30-42.
23. Lin CT, Wong CI, Chan WY, et al. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest 1990;62:713-24.
24. Lin CT, Chan WY, Chen W, et al. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 1993;68:716-27.
25. Chang KP, Hsu CL, Chang YL, et al. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: A possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol 2008;44:784-92.
26. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006;24:5414-8.
27. Shao JY, Li YH, Gao HY, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004;100:1162-70.
28. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005;102:7677-82.
29. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 2004;10:43-52.
30. Ho S, Leung WT, Yuen J, Johnson PJ. Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy. Eur J Cancer B Oral Oncol 1996;32B:377-80.
31. Qian CN, Zhang CQ, Guo X, et al. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 2000;88:255-61.
32. Xu J, Menezes J, Prasad U, Ahmad A. Elevated serum-levels of transforming growth factor β1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int JCancer 1999;84:396-9.
33. Conrads TP, Zhou M, Petricoin EF III, Liotta L, Veenstra TD. Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn 2003;3:411-20.
34. Xiao T, Ying W, Li L, et al. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics 2005;4:1480-6.
35. Ma BB, King A, Lo YM, et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int JRadiat Oncol Biol Phys 2006;66:714-20.
36. Okudaira T, Yamamoto K, Kawakami H, et al. Transactivation of CCL20 gene by Epstein-Barr virus latent membrane protein 1. Br J Haematol 2006;132:293-302.
37. Yamauchi K, Akbar SM, Horiike N, Michitaka K, Onji M. Increased serum levels of macrophage inflammatory protein-3α in chronic viral hepatitis: prognostic importance of macrophage inflammatory protein-3α during interferon therapy in chronic hepatitis C. J Viral Hepat 2002;9:213-20.
38. Yamauchi K, Akbar SM, Horiike N, Michitaka K, Onji M. Increased serum levels of macrophage inflammatory protein-3α in hepatocellular carcinoma: relationship with clinical factors and prognostic importance during therapy. Int J Mol Med 2003;11:601-5.